Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines

Gynecologic Oncology

Volumn 117, Issue 2, 2010, Pages 202-210

  Marverti, Gaetano ^a   Ligabue, Alessio ^a   Guerrieri, Davide ^a   Paglietti, Giuseppe ^b   Piras, Sandra ^b   Costi, Maria P ^a   Farina, Davide ^a   Frassineti, Chiara ^a   Monti, Maria G ^a   Moruzzi, Maria S ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cisplatin; Folate cycle inhibitors; Polyamine analogues; Quinoxalines; SSAT

Indexed keywords

CISPLATIN; DIETHYLDERIVATIVE OF NORSPERMINE; FLUOROURACIL; FOLIC ACID; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; N1,N12 BISETHYLSPERMINE; NORSPERMINE; POLYAMINE DERIVATIVE; QUINOXALINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SPERMIDINE SPERMINE N1 ACETYLTRANSFERASE; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL KILLING; CHEMOSENSITIVITY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; POLYAMINE METABOLISM; PRIORITY JOURNAL;

ACETYLTRANSFERASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; OVARIAN NEOPLASMS; QUINOXALINES; REACTIVE OXYGEN SPECIES; SPERMINE;

EID: 77950189269     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.11.030     Document Type: Article

References (55)

1. Ozols R.F., Bookman M.A., Connolly D.C., Daly M.B., Godwin A.K., Schilder R.J., et al. Focus on epithelial ovarian cancer. Cancer Cell 5 (2004) 19-24
2. Sundar S., Symonds R.P., Decatris M.P., Kumar D.M., Osman A., Vasanthan S., et al. Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol. Oncol. 94 (2004) 502-508
3. Gil-Delgado M.A., Guinet F., Castaing D., Adam R., Coeffic D., Durrani A.K., et al. Prospective phase II trial of irinotecan, 5-fluorouacil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. Am. J. Clin. Oncol. 24 (2001) 101-105
4. Goldberg R.M., Kaufmann S.H., Atherton P., Sloan J.A., Adjei A.A., Pitot H.C., et al. A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. Ann. Oncol. 13 (2002) 1674-1680
5. Parker W.B., and Cheng Y.C. Metabolism and mechanism of action of 5fluorouracil. Pharmacol. Ther. 48 (1990) 381-395
6. Peters G.J., Backus H.H., Freemantle S., van Triest B., Codacci-Pisanelli G., van der Wilt C.L., et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim. Biophys. Acta 1587 (2002) 194-205
7. Zhang W., Ramdas L., Shen W., Song S.W., Hu L., and Hamilton S.R. Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2. Cancer Biol. Ther. 2 (2003) 572-578
8. Maxwell P.J., Longley D.B., Latif T., Boyer J., Allen W., Lynch M., et al. Identification of 5-fluorouracil inducible target genes using cDNA microarray profiling. Cancer Res. 63 (2003) 4602-4606
9. Boyer J., McLean E.G., Aroori S., Wilson P., McCulla A., Carey P.D., et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil,oxaliplatin, and irinotecan. Clin. Cancer Res. 10 (2004) 2158-2167
10. Snyder R.D. Polyamine depletion is associated with altered chromatin structure in HeLa cells. Biochem. J. 260 (1989) 697-704
11. Marverti G., Ligabue A., Paglietti G., Corona P., Piras S., Vitale G., et al. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. Eur. J. Pharmacol. 615 (2009) 17-26
12. Kelland L.R. Preclinical perspectives on platinum resistance. Drugs 59 (2000) 1-8
13. Lai G.M., Ozols R.F., Smyth J.F., Young R.C., and Hamilton T.C. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem. Pharmacol. 37 (1988) 4597-4600
14. Masuda H., Ozols R.F., Lai G., Fojo A., Rothembert M., and Hamilton T.C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells. Cancer Res. 48 (1988) 5713-5716
15. Wallace H.M. Polyamines and their role in human disease: an introduction. Biochem. Soc. Trans. 31 (2003) 354-355
16. Subhi A.L., Diegelman P., Porter C.W., Tang B., Lu Z.J., Markham G.D., et al. Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites. J. Biol. Chem. 278 (2003) 49868-49873
17. Belting M., Borsig L., Fuster M.M., Brown J.R., Persson L., Fransson L.A., et al. Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 371-376
18. Coleman C.S., and Pegg A.E. Polyamine analogues inhibit the ubiquitination of spermidine/spermine N1-acetyltransferase and prevent its targeting to the proteasome for degradation. Biochem. J. 358 (2001) 137-145
19. Averill-Bates D.A., Agostinelli E., Przybytkowski E., and Mondovi B. Aldehyde dehydrogenase and cytotoxicity of purified bovine serumam ine oxidase and spermine in Chinese hamster ovary cells. Biochem. Cell Biol. 72 (1994) 36-42
20. Ha H.C., Woster P.M., Yager J.D., and Casero Jr. R.A. The role of polyamine catabolism in polyamine analogue-induced programmed cell death. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 11557-11562
21. Chen Y., Kramer D.L., Diegelman P., Vujcic S., and Porter C.W. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 61 (2001) 6437-6444
22. Choi W., Gerner E.W., Ramdas L., Dupart J., Carew J., Proctor L., et al. Combination of 5-fluorouracil and N1,N11-diethylnorspermine markedly activates spermidine/spermine N1-acetyltransferase expression, depletes polyamines, and synergistically induces apoptosis in colon carcinoma cells. J. Biol. Chem. 280 (2005) 3295-3304
23. Allen W.L., McLean E.G., Boyer J., McCulla A., Wilson P.M., Coyle V., et al. The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Mol. Cancer Ther. 6 (2007) 128-137
24. 12-bis(ethyl)spermine effect on growth of cis-diamminedichloroplatinum(II)-sensitive and -resistant human ovarian carcinoma cell lines. Int. J. Cancer 78 (1998) 33-40
25. 12-bis(ethyl)spermine and to cisplatin. Carcinogenesis 26 (2005) 1677-1686
26. Loriga M., Fiore M., Sanna P., and Paglietti G. Quinoxaline chemistry: Part 4. 2-(R)-anilinoquinoxalines as non classic antifolate agents. Synthesis, structure elucidation and evaluation of in vitro anticancer activity. Il Farmaco 50 (1995) 289-301
27. Loriga M., Moro P., Sanna P., and Paglietti G. Quinoxaline chemistry: Part 8. 2-[Anilino]-3-[Carboxy]-6(7)-substituted quinoxalines as non classical antifolate agents. Synthesis and evaluation of in vitro anticancer, anti-HIV and antifungal activity. Il Farmaco 52 (1997) 531-537
28. Loriga M., Piras S., Paglietti G., Costi M.P., and Venturelli A. Quinoxaline chemistry: Part 15. 4-[2-Quinoxalylmethylenimino]benzoylglutamates and -benzoates, 4-[2-quinoxalylmethyl-N-methylamino]-benzoylglutamates as analogues of classical antifolate agents. Synthesis, elucidation of structures and in vitro evaluation of antifolate and anticancer activities. Il Farmaco 58 (2003) 51-61
29. Piras S., Loriga M., and Paglietti G. Quinoxaline chemistry: Part 17. 4[3,6(7)disubstituted-2-quinoxalinyl-oxy]phenylacetate and phenylacetylglutamate analogues of methotrexate. Synthesis and evaluation of in vitro anticancer activity. Farmaco 59 (2004) 185-194
30. Piras S., Loriga M., Carta A., Paglietti G., Costi M.P., and Ferrari S. Novel 3.Benzoyl-2-piperazinylquinoxaline derivatives as potential antitumor agents. J. Heterocyclic Chem. 43 (2006) 541-551
31. Andrews P.A., and Albright K.D. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 52 (1992) 1895-1901
32. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folic phenol reagent. J. Biol. Chem. 193 (1951) 265-275
33. Kueng W., Siber E., and Eppenberger U. Quantification of cells cultured on 96-well plates. Anal. Biochem. 182 (1989) 16-19
34. -ΔΔCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagn. Mol. Pathol. 15 (2006) 56-61
35. 1-acetyltransferase in human large cell lung carcinoma. Biochem. J. 270 (1990) 615-620
36. Seiler N.B., Knodgen B., and Eisenbess F. Determination of di- and polyamines by high-performance liquid-chromatographic separation of their 5-dimethylaminonaphtalene-1-sulfonyl derivatives. J. Chromatogr. 145 (1978) 29-39
37. Marzano C., Gandin V., Folda A., Scutari G., Bindoli A., and Rigobello M.P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 42 (2007) 872-881
38. Tagliaferri P., Katsaros D., Clair T., Ally S., Tortora G., Neckers L., et al. Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cyclic AMP analogues. Cancer Res. 48 (1988) 1642-1650
39. Cho Y.S., and Cho-Chung Y.S. Antisense protein kinase A RIα acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy. Clin. Cancer Res. 9 (2003) 1171-1178
40. Scanlon K.J., and Kashani-Sabet M. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 650-653
41. Hector S., Tummala R., Kisiel N.D., Diegelman P., Vujcic S., Clark K., Fakih M., Kramer D.L., Porter C.W., and Pendyala L. Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine. Cancer Chemother. Pharmacol. 62 (2008) 517-527
42. 12-bis(ethyl)spermine. In: Bardocz S., Koninkx J., Grillo M.A., and White A. (Eds). Biologically active amines in food processing and amines produced by bacteria, and polyamines and tumour growth. COST 917, Biologically active amines in food Vol. III (1999) 94-98
43. Kee K., Vujcic S., Merali S., Diegelman P., Kisiel N., Powell C.T., et al. Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells. J. Biol. Chem. 279 (2004) 27050-27058
44. Shappell N.W., Fogel-Petrovic M.F., and Porter C.W. Regulation of spermidine/spermine N1-acetyltransferase by intracellular polyamine pools. Evidence for a functional role in polyamine homeostasis. FEBS Lett. 321 (1993) 179-183
45. Basu H.S., Schwietert H.C., Feuerstein B.G., and Marton L.J. Effects of variation in the structure of spermine on the association with DNA and the induction of DNA conformational changes. Biochem. J. 269 (1990) 329-334
46. Basu S., Feuerstein B.G., Dennis F.D., Lubich W.P., Bergeron R.J., Samejima K., et al. Correlation between the effects of polyamine analogues on DNA conformation and cell growth. Cancer Res. 49 (1989) 5591-5597
47. Gao H., Yamasaki E.F., Chan K.K., Shen L.L., and Snapka R.M. Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIalpha/beta poison. Cancer Res. 60 (2000) 5937-5940
48. Gao H.L., Huang K.C., Yamasaki E.F., Chan K.K., Chohan L., and Snapka R.M. XK469, a selective topoisomerase IIb poison. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 12168-12173
49. Alm K., Berntsson P., and Oredsson S.M. Topoisomerase II is nonfunctional in polyamine-depleted cells. J. Cell. Biochem. 75 (1999) 46-55
50. Hector S., Porter C.W., Kramer D.L., Clark K., Prey J., et al. Polyamine catabolism in platinum drug action: interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Mol. Cancer Ther. 3 (2004) 813-822
51. Varma R., Hector S., Greco W.R., Clark K., Hawthorn L., Porter C., et al. Platinum drug effects on the expression of gene in polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother. Pharmacol. 59 (2007) 711-723
52. Boyer J., Allen W.L., McLean E.G., Wilson P.M., McCulla A., Moore S., et al. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 66 (2006) 2765-2777
53. 1-acetyltransferease activity by novel spermine analogs. Mol. Pharmacol. 52 (1997) 69-74
54. Snyder R.D., Beach D.C., and Loudy D.E. Anti-mitochondrial effects of bisethyl polyamines in mammalian cells. Anticancer Res. 14 (1994) 347-356
55. Dredge K., Kink J.A., Johnson R.M., Bytheway I., and Marton L.J. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer. Cancer Chemother. Pharmacol. 65 (2009) 191-195